ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2024
Interim 2023/24 influenza A vaccine effectiveness: VEBIS European primary care and hospital multicentre studies, September 2023 to January 2024.
Abstract read
In one paragraph
Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Strain-specific differences in the response to egg-derived versus recombinant protein influenza vaccines.Journal of virology · 2026Article
- Short-term safety and reactogenicity of same-day COVID-19 and influenza vaccination in very old, community-dwelling adults.European geriatric medicine · 2026Observational
- Strain-specific differences in the response to egg-derived versus recombinant protein influenza vaccines.bioRxiv : the preprint server for biology · 2026Article
- Article
- Brand-specific influenza vaccine effectiveness in three Nordic countries during the 2024-2025 season: a target trial emulation study based on registry data.The Lancet regional health. Europe · 2026Article
- Vaccine effectiveness dynamics against influenza and SARS-CoV-2 in community-tested patients in France 2023-2024.Emerging microbes & infections · 2025Article
- Influenza vaccine effectiveness among primary and secondary school students in Shenzhen during the 2023/24 influenza season.Emerging microbes & infections · 2025Article
- Influenza Vaccine Effectiveness Against Medically Attended Outpatients Illness, United States, 2023-2024 Season.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Article
- Vaccine Effectiveness Against Influenza A(H1N1), A(H3N2), and B-Associated Hospitalizations, United States, 1 September 2023 to 31 May 2024.The Journal of infectious diseases · 2025Article
- Effectiveness of the 2023 Southern Hemisphere Influenza Vaccine Against Outpatient Influenza-Like Illness: A Multi-Country Test-Negative Design Study.Open forum infectious diseases · 2025Article
- Effectiveness of Cell Culture-Based Influenza Vaccine, 2023-2024.Journal of the Pediatric Infectious Diseases Society · 2025Article
- A bacteria-based search for drugs against avian and swine flu yields a potent and resistance-resilient channel blocker.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Article
- Early and Late Influenza Vaccine Effectiveness in South Korea During the 2023-2024 Season.Vaccines · 2025Article
- Early vaccine effectiveness estimates against medically attended laboratory-confirmed influenza based on influenza surveillance, Beijing, China, 2024/25 season.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Influenza vaccine effectiveness against detected infection in the community, France, October 2024 to February 2025.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Effectiveness of influenza vaccination in preventing confirmed influenza cases and hospitalizations in Northern Spain, 2023/24 season: A population-based test-negative case-control study.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2025Article
- Effectiveness of 2023 southern hemisphere influenza vaccines against severe influenza-associated illness: pooled estimates from eight countries using the test-negative design.The Lancet. Global health · 2025Article
- Interim 2024/25 influenza vaccine effectiveness: eight European studies, September 2024 to January 2025.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
48 authors.
Marine MaurelEpiconcept, Paris, France.
Jennifer HowardEpiconcept, Paris, France.
Esther KisslingEpiconcept, Paris, France.
Francisco PozoCIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Madrid, Spain.
Gloria Pérez-GimenoNational Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
Silke BudaDepartment for Infectious Disease Epidemiology, Respiratory Infections Unit, Robert Koch Institute, Berlin, Germany.
Noémie SèveSorbonne Université, INSERM, Institut Pierre Louis d'épidémiologie et de Santé Publique (IPLESP UMRS 1136), Paris, France.
Adele McKennaHSE Health Protection Surveillance Centre, Dublin, Ireland.
Adam MeijerNational Institute for Public Health and the Environment, Centre for Infectious Diseases Control, Bilthoven, the Netherlands.
Ana Paula RodriguesEpidemiology Department, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal.
Iván Martínez-BazInstituto de Salud Pública de Navarra - IdiSNA - CIBERESP, Pamplona, Spain.
Ivan MlinarićCroatian Institute of Public Health, Zagreb, Croatia.
Neus Latorre-MargalefPublic Health Agency of Sweden, Stockholm, Sweden.
Gergő TúriNational Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary.
Mihaela LazărCantacuzino National Military Medical Institute for Research and Development, Bucharest, Romania.
Clara MazagatosNational Centre for Epidemiology, Institute of Health Carlos III, Madrid, Spain.
Aitziber EcheverriaInstituto de Salud Pública de Navarra - IdiSNA - CIBERESP, Pamplona, Spain.
Stephen AbelaInfectious Disease Prevention and Control Unit (IDCU), Health Promotion and Disease Prevention, Msida, Malta.
Marc BourgeoisDepartment of Infectious Diseases, CHU UCL Namur (site Godinne), Université catholique de Louvain, Yvoir, Belgium.
Ausenda MachadoEpidemiology Department, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal.
Ralf DürrwaldNational Reference Centre for Influenza, Robert Koch Institute, Berlin, Germany.
Goranka PetrovićCroatian Institute of Public Health, Zagreb, Croatia.
Beatrix OrosziNational Laboratory for Health Security, Epidemiology and Surveillance Centre, Semmelweis University, Budapest, Hungary.
Ligita JancorieneClinic of Infectious Diseases and Dermatovenerology, Institute of Clinical Medicine, Medical Faculty, Vilnius University, Vilnius, Lithuania.
Alexandru MarinDr Victor Babes Clinical Hospital of Infectious and Tropical Diseases, Bucharest, Romania.
Petr HusaUniversity Hospital Brno and Masaryk University, Brno, Czechia.
Roisin DuffyHSE Health Protection Surveillance Centre, Dublin, Ireland.
Frederika DijkstraNational Institute for Public Health and the Environment, Centre for Infectious Diseases Control, Bilthoven, the Netherlands.
Virtudes Gallardo GarcíaServicio de Vigilancia y Salud Laboral, Dirección General de Salud Pública y Ordenación Farmacéutica, Consejería de Salud y Consumo, Andalucía, Spain.
Luise GoerlitzDepartment for Infectious Disease Epidemiology, Respiratory Infections Unit, Robert Koch Institute, Berlin, Germany.
Vincent EnoufCentre National de Référence Virus des Infections Respiratoire (CNR VIR), Institut Pasteur Université Paris Cité, Paris, France.
Charlene BennettNational Virus Reference Laboratory, University College Dublin, Dublin, Ireland.
Mariëtte HooiveldNivel, Utrecht, the Netherlands.
Raquel GuiomarLaboratório Nacional Referência Gripe e outros Vírus Respiratórios, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal.
Camino Trobajo-SanmartínInstituto de Salud Pública de Navarra - IdiSNA - CIBERESP, Pamplona, Spain.
Vesna Višekruna VučinaCroatian Institute of Public Health, Zagreb, Croatia.
Tove Samuelsson HageyPublic Health Agency of Sweden, Stockholm, Sweden.
Ana Sofía Lameiras AzevedoServicio de vigilancia y control epidemiológico, Subdirección general de Epidemiología y Vigilancia de la Salud, Dirección General de Salud pública, Valencia, Spain.
Jesús CastillaInstituto de Salud Pública de Navarra - IdiSNA - CIBERESP, Pamplona, Spain.
Gerd XuerebDepartment of Child and Adolescent Health, Mater Dei Hospital, Msida, Malta.
Bénédicte DelaereDepartment of Infectious Diseases, CHU UCL Namur (site Godinne), Université catholique de Louvain, Yvoir, Belgium.
Verónica GómezEpidemiology Department, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisbon, Portugal.
Kristin TolksdorfDepartment for Infectious Disease Epidemiology, Respiratory Infections Unit, Robert Koch Institute, Berlin, Germany.
Sabrina BacciEuropean Centre for Disease Prevention and Control, Stockholm, Sweden.
Nathalie NicolayEuropean Centre for Disease Prevention and Control, Stockholm, Sweden.
Marlena KaczmarekEuropean Centre for Disease Prevention and Control, Stockholm, Sweden.
Angela Mc RoseEpiconcept, Paris, France.
European IVE groupThe members of the European IVE group are listed under Acknowledgements.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Influenza A viruses circulated in Europe from September 2023 to January 2024, with influenza A(H1N1)pdm09 predominance. We provide interim 2023/24 influenza vaccine effectiveness (IVE) estimates from two European studies, covering 10 countries across primary care (EU-PC) and hospital (EU-H) settings. Interim IVE was higher against A(H1N1)pdm09 than A(H3N2): EU-PC influenza A(H1N1)pdm09 IVE was 53% (95% CI: 41 to 63) and 30% (95% CI: -3 to 54) against influenza A(H3N2). For EU-H, these were 44% (95% CI: 30 to 55) and 14% (95% CI: -32 to 43), respectively.
Indexed as
Influenza A Virus, H1N1 SubtypeInfluenza, HumanInfluenza VaccinesCase-Control StudiesHospitalsHumansInfluenza A Virus, H3N2 SubtypeInfluenza B virusPrimary Health CareSeasonsVaccinationInfluenza VaccinesEuropeinfluenzamulticentre studytest-negative designvaccine effectiveness
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.